Month: May 2019

Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a clinical patent for arfolitixorin in the United States. The patent expires in 2038 and is the first in a series of clinical patent …

Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States Read More »

Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a clinical patent for arfolitixorin in the United States. The patent expires in 2038 and is the first in a series of clinical patent applications to reach grant.  It relates to a method of increasing blood concentration of deoxyuridine, a blood biomarker for inhibition of tumor growth in human cancer treatment.

Isofol Reports 58 % Overall Response Rate

Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from an open-label extension Phase 1/2a study, ISO-CC-005, of arfolitixorin as part of the …

Isofol Reports 58 % Overall Response Rate Read More »

Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from an open-label extension Phase 1/2a study, ISO-CC-005, of arfolitixorin as part of the first-line treatment regimen in patients with metastatic colorectal cancer (mCRC). Preliminary response assessment data from 19 patients treated for 8-32 weeks showed a best overall response rate (ORR) in 58% of patients (11/19). These patients were treated with the selected dose regimen of 120 mg/m2 arfolitixorin and 5-fluorouracil (5-FU) with either irinotecan or oxaliplatin (ARFIRI/ARFOX) (ref. 1). Best ORR is defined as a greater than 30 % reduction in tumor size from baseline.

Scroll to Top